0.78 USD
↘ 0.02 (2.28%)AT CLOSE (11:59 AM EDT)
Outlook Therapeutics, Inc. Common Stock
OTLKNASDAQ • USD
0.81
↗ 0.03 (4.03%)
POST MARKET (AS OF 07:56 PM EDT)
Post Market
AS OF 07:56 PM EDT
0.81
↗ 0.03 (4.03%)
Market: CLOSED
Open?$0.78
High?$0.85
Low?$0.73
Prev. Close?$0.79
Volume?12.1M
Avg. Volume?25.6M
VWAP?$0.78
Rel. Volume?0.47x
Bid / Ask
Bid?$0.67 × 100
Ask?$0.91 × 100
Spread?$0.24
Midpoint?$0.79
Valuation & Ratios
Market Cap?117.4M
Shares Out?120.9M
Float?83.0M
Float %?99.9%
P/E Ratio?N/A
P/B Ratio?-4.05
EPS?-$0.32
Dividend?0.00%
Ex-Dividend?N/A
Outlook Therapeutics, Inc. Common Stock (OTLK) is currently trading at $0.78. OTLK shows a split signal: technical indicators suggest "Buy" while underlying fundamentals indicate "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (164.4%) and a bearish Death Cross on the long-term moving averages. On the valuation front, OTLK trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Jun 5, 2026.
News
Profile
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Employees
17
Market Cap
120.3M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2016-05-13
Address
111 S. WOOD AVENUE
ISELIN, NJ 08830
Phone: (609) 619-3990
ISELIN, NJ 08830
Phone: (609) 619-3990
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?65
Short Sent.?56
Piotroski F-Score?0/9Weak
Altman Z-Score?-46.60Distress
Confidence?45%Low
Short InterestHigh
Short % of Float?10.95%High
Short Interest?9.1M
Days to Cover?2.2
Free Float83.0M
Avg Daily Volume4.2M
Settlement Date2026-05-15
Financial Health
Current Ratio?0.54Weak
Quick Ratio?0.45Weak
Cash Ratio?0.20Low
Debt/Equity?-0.93Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?-4.05CHEAP▾
S&P97
P/S?276.24HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-3.2CHEAP▾
S&P97
EV/Sales?321.48HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?164.4%STRONG▾
Peers50
S&P97
ROA?-217.7%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$136.6M
Fundamentals ratios updated end of day